Close

Industry Experts Combine to Create Safer Intravenous Delivery

25 February 2019

February 25, 2019 Rome, Italy – The Italian Biochemical Institute (IBI) "Lorenzini", Comecer, and Particle Measuring Systems (PMS) recently partnered to leverage and combine the expertise of each entity to design a new drug delivery system and a filling line to safely and effectively manufacture it. A Quality Risk Management (QRM) approach was used as the basis to meet the distinctive needs of the aseptic filling line and ensure that regulatory needs were met.

This partnership started when IBI designed a new approach to drug infusions deliveries, patented as “Espresso®”. “Espresso was created to ensure the safe delivery of sterile intravenous medication to patients”, said J. Khevenhüller, CEO at The Italian Biochemical Institute (IBI). “Following the initial project, we needed a way to safely mass produce Espresso. However, because of its unique design, existing filling lines could not meet our needs, so we contacted Comecer to create something new.”

“When Lorenzini approached us with their Espresso approach, we were immediately intrigued by the design challenges it presented.  We took on the project to create something with a completely fresh approach to ensure the product sterility”, said S. Penazzi, Sales Area Manager Pharma Division at Comecer. “We had worked with PMS in the past and invited them to join our development team to leverage their industry knowledge.”

“Our Advisory Team has experience working with manufacturers to ensure they meet regulatory needs and to provide safe drugs to their customers, and we were confident our background could help solve the needs of the Espresso approach”, said Maurizio Della Pietra, Global Data Management Specialist and Process Advisor at Particle Measuring Systems. He continued, “Our insights to regulatory requirements, plus Comecer’s expertise in building filling lines, combined to create a forward-thinking, effective result.”

“As aseptic manufacturers develop unique new solutions, the requirement for increasingly complex manufacturing requirements to meet quality standards and to ensure the safety of drugs arises”, said Gianni Scialo, VP Pharmaceutical, Particle Measuring Systems. He continued, “Creative partnerships such as that between IBI, Comecer, and PMS will become increasingly important to meet these needs."

Learn more

About Particle Measuring Systems
Particle Measuring Systems Inc. (PMS), a subsidiary of Spectris plc, is a global technology leader and expert in contamination monitoring, the inventor of laser particle counting, and now is the leading provider of solutions for monitoring and controlling many forms of contamination that impact companies that manufacture in ultra-clean environments.  For more information visit pmeasuring.com

About Comecer
Comecer develops and manufactures high-tech systems in the field of Aseptic Processing and Containment for the Pharmaceutical and Nuclear Medicine Industries, specialising in isolation technology solutions for regenerative medicine and tissue engineering.
We aim to contribute to progress and preserve life through the development of highly innovative technologies and sustainable solutions, according to the latest GMP (Good Manufacturing Practice) regulations. Learn more at www.comecer.com

About The Italian Biochemical Institute (IBI) "Lorenzini" 
IBI,  IBIGEN group, is a company that has been producing and selling injectable products all over the world for 100 years. It is also present in hospitals (Parental Products for Hospitals). Expert in aseptic dosing and ß-lactam products, it is a vertically integrated company working from the raw material through the finished product to sales distribution and the patient’s bed. Learn more at www.ibi-lorenzini.it 

Media contacts

Nina Morton
Particle Measuring Systems
Boulder, CO 80301
Tel: 303-443-7100
nmorton@pmeasuring.com

IBI Biochemical Institute
T: +39 06 921501
scolaneri@ibi-lorenzini.com

COMECER S.p.A.
Italy
T: +39 0546 656375
marketing@comecer.com  

Latest news

undefined

REVER3MAB: "An ambitious project for the development of an innovative biological drug"?

IBI collaborates in the development of an innovative biological drug to revert resistance to conventional cancer treatments: project: REVER3MAB (EU, State and Region)

Read all
undefined

Seguiamo i farmaci fino a voi

Cinquanta milioni di investimento digitale e un forte impegno nella tracciabilità dei prodotti

Read all
undefined

Ibi partecipa all'iniziativa UniCredit 4 Growth

Read all

Thank you

We sent you an email. To activate the newsletter click on the link you will find in the message, thank you!

Sign up for the newsletter


Dichiarazione in merito al GDPR (Regolamento Generale Protezione dei Dati)

In caso di sottoscrizione Newsletter dovrai confermare l’iscrizione per mezzo di mail di conferma inviata all’indirizzo inserito. In tal caso il trattamento prevede:

la profilazione dell’utente in gruppi, status, preferenze secondo quanto indicato e dedotto dalle informazioni inviate tramite il form o successiva autonoma profilazione.
l’utilizzo del dato per l’invio di comunicazione a mezzo digitale (email, whatsapp) e non (cartaceo) avente scopo informativo/commerciale.
l'utilizzo della mail per la generazione di campagne marketing e informative personalizzate, digitali e non.

Cancel
CHIUDI


Private area


Log in to restricted area


Registration


Notice on the treatment of personal data

Dear visitor, in the following sections we will describe how the reserved area of the www.ibi-lorenzini.it website is managed as far as processing personal data of users. The notice is issued pursuant to art. 13 of EU Regulation 679/2016 (hereinafter also the Regulation) on the protection of natural persons with regard to the processing of personal data and on the free movement of such data, and applies to those who interact with the website of Istituto Biochimico Italiano Giovanni Lorenzini S.p.A. (hereinafter I.B.I.), which can be accessed at the following address: www.ibi-lorenzini.it, the opening page of the official I.B.I. website. The notice only applies to the I.B.I. website. It does not apply to any other websites that the user may access through links.

  1. The processing of the personal data that you supply, which are also used for the creation of your user profile, and which will be included in the “Doctors’ Details” database, has the following purposes:
  • carry out medical sales related activities for drugs for human consumption. Istituto Biochimico Italiano Giovanni Lorenzini S.p.A. and Ibigen S.r.l., part of the same company group (hereinafter also Ibigen Group), carry out such activities in compliance with the provisions of the current regulations, with particular, but not exclusive, attention to Italian Legislative Decree no. 219 of 24.04.2006 and subsequent modifications. In view of the objectives of the Ibigen Group, it is important to point out that the processing activities do not deal with any special data. The supply of the data for the medical sales activities is necessary, and failure to provide consent will make it impossible for us to fulfil the above objectives;

  • forwarding of invitations or information on congresses, conferences, seminars, communications on initiatives promoted or sponsored by the Ibigen group, regular or occasional publications, information on new products, methods and services. Such activities are carried out by e-mail, fax, SMS, normal post or telephone. The supply of the data for such purposes is optional, and failure to supply them will result in the information not being forwarded.

  1. As far as the creation of your profile on our website, we remind you that your password is strictly confidential and should not be disclosed.
  2. Your data will not be disclosed, but may be shared with individuals, companies, associations or professional studios providing support or consultancy services to the Ibigen Group, the medical sales representative network, our suppliers and any sub-suppliers - from time to time entrusted with activities connected with the above objectives -, mailing or statistical survey companies, or companies for the forwarding of scientific documentation, and individuals authorised to access the data by law and/or pursuant to secondary regulations.
  3. Such people may only acquire knowledge of your personal data for the above mentioned purposes.
  4. The Owners of the Treatment (Data Controllers) are the two companies of the Ibigen Group with legal headquarters at Via Fossignano no. 2, Aprilia (LT), Italy.
  5. Personal data are processed using manual and automated means, for the time necessary for reaching the objectives for which they were collected. Special safety measures are in place to avoid data loss, unlawful or incorrect use and unauthorised access.
  6. Lastly, we also inform you that you can at any time exercise the rights contemplated by the Regulation, and in particular request access to the data, their correction, update and block, or you can withdraw your consent, or request the limitation of the processing or the cancellation of the data. As data subject, you also have the right to issue a complaint with the relevant control Authority. Such rights may be exercised in writing to the following e-mail address: info@ibi-lorenzini.com.
  7. The Data Protection Officer may be contacted at the following e-mail address: dpo_ibi@protectiontrade.it

* Required fields
Cancel